In a research report sent to investors today, Cantor Fitzgerald analyst Irina Rivkind maintained a Hold rating on Ligand Pharmaceuticals (NASDAQ:LGND) with a $49 price target, as the company updated its 3Q:14 …
In a research note published Tuesday, Roth Capital analyst Joseph Pantginis assigned a Buy rating on Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a $92 price …
Ligand Pharma (NASDAQ:LGND) partner GlaxoSmithKline (NYSE:GSK) announced it received FDA approval for the sNDA of Promacta for treatment of cytopenia in patients with …
In a research report released today, Cantor Fitzgerald analyst Irina Rivkind maintained a Hold rating on Ligand Pharmaceuticals (LGND) and raised her price target to $49 (from $45), as her big picture …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on Ligand Pharmaceuticals (LGND) and a $92.00 price target, following LGND’s second-quarter results, …
In a research note published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceuticals (LGND) with a $92 price …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceuticals (LGND) with a $92 price target, following today’s news that LGND’s partner …
In a report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) with a $92.00 price target, following LGND’s announcemet that total revenue for 2Q14 …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) and a price target of $92.00 following …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Ligand Pharmaceuticals, Inc. (LGND), and a price target of $92.
